Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
| Title: | Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study |
|---|---|
| Authors: | Fletcher K.; Cortellini A.; Ganta T.; Kankaria R.; Song H.; Ye F.; Irlmeier R.; Debnath N.; Saeed A.; Radford M.; Alahmadi A.; Diamond A.; Hoimes C.; Presley C. J.; Owen D. H.; Abou Alaiwi S.; Nassar A. H.; Lamberti G.; Perrone F.; Buti S.; Giusti R.; Filetti M.; Vanella V.; Mallardo D.; Sussman T. A.; Galetta D.; Kalofonou F.; Daniels E.; Ascierto P. A.; Pinato D. J.; Nebhan C.; Berg S.; Choueiri T. K.; Marron T. U.; Wang Y.; Naqash A. R.; Johnson D. B. |
| Contributors: | Fletcher K.; Cortellini A.; Ganta T.; Kankaria R.; Song H.; Ye F.; Irlmeier R.; Debnath N.; Saeed A.; Radford M.; Alahmadi A.; Diamond A.; Hoimes C.; Presley C.J.; Owen D.H.; Abou Alaiwi S.; Nassar A.H.; Lamberti G.; Perrone F.; Buti S.; Giusti R.; Filetti M.; Vanella V.; Mallardo D.; Sussman T.A.; Galetta D.; Kalofonou F.; Daniels E.; Ascierto P.A.; Pinato D.J.; Nebhan C.; Berg S.; Choueiri T.K.; Marron T.U.; Wang Y.; Naqash A.R.; Johnson D.B. |
| Publication Year: | 2024 |
| Collection: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: | Anti-PD-1 therapy; Geriatric population; Immune-related adverse event; Immunotherapy; Melanoma |
| Description: | Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients ≥80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy. We determined response rate, overall survival (OS), and progression-free survival (PFS) in patients who discontinued therapy early ( |
| Document Type: | article in journal/newspaper |
| File Description: | ELETTRONICO |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38838764; info:eu-repo/semantics/altIdentifier/wos/WOS:001331314000001; volume:596; firstpage:1; lastpage:5; numberofpages:5; journal:CANCER LETTERS; https://hdl.handle.net/11585/980793; https://www.sciencedirect.com/science/article/pii/S0304383524003951 |
| DOI: | 10.1016/j.canlet.2024.217001 |
| Availability: | https://hdl.handle.net/11585/980793; https://doi.org/10.1016/j.canlet.2024.217001; https://www.sciencedirect.com/science/article/pii/S0304383524003951 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.E7FC4AD3 |
| Database: | BASE |